Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Share-based Compensation (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Share-based Compensation data on record, last reported at -$32.3 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 2.6% year-over-year to -$32.3 million; the TTM value through Sep 2025 reached -$861000.0, down 100.91%, while the annual FY2023 figure was $67.2 million, N/A changed from the prior year.
  • Share-based Compensation reached -$32.3 million in Q4 2025 per VRDN's latest filing, down from $11.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $61.5 million in Q4 2023 and bottomed at -$33.2 million in Q4 2024.
  • Average Share-based Compensation over 5 years is $3.7 million, with a median of $4.9 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 547.48% in 2021, then tumbled 541.53% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at -$3.5 million in 2021, then tumbled by 317.01% to -$14.5 million in 2022, then surged by 524.37% to $61.5 million in 2023, then tumbled by 153.96% to -$33.2 million in 2024, then rose by 2.6% to -$32.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were -$32.3 million in Q4 2025, $11.2 million in Q3 2025, and $10.8 million in Q2 2025.